Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198062 | 0.73 | DRD2 (0.44) | — | |
| SCHEMBL8609337 | 0.72 | CYP2C9 (0.34) | — | |
| SCHEMBL17974163 | 0.71 | ESR1 (0.40) | ESR1ESR2 | |
| SCHEMBL7317272 | 0.67 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL9391610 | 0.67 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL10682685 | 0.67 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL7868319 | 0.66 | PTPN7 (0.36) | ESR1ESR2 | |
| SCHEMBL18204707 | 0.66 | HTR6 (0.42) | ESR1ESR2 | |
| SCHEMBL30901243 | 0.64 | MAOA (0.39) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL18204598 | 0.64 | HTR6 (0.44) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1066187-A | — | — | None | — | — | JP | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011087712-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | ESR1 2188/4885ESR2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.